GE HealthCare Technologies (NASDAQ:GEHC) Issues Quarterly Earnings Results

GE HealthCare Technologies (NASDAQ:GEHC) announced its quarterly earnings results on Wednesday. The company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.20 by $0.14, FiscalAI reports. GE HealthCare Technologies had a net margin of 9.96% and a return on equity of 20.45%. The business had revenue of $5.51 billion during the quarter, compared to analysts’ expectations of $5.35 billion. During the same period last year, the business earned $1.07 earnings per share. The business’s revenue for the quarter was up 7.2% on a year-over-year basis.

Here are the key takeaways from GE HealthCare Technologies’ conference call:

• GE HealthCare raised its full-year 2026 guidance, now expecting approximately 4% organic revenue growth, 15.5%–15.7% adjusted EBIT margin, adjusted EPS of $4.95–$5.05, and free cash flow above $1.6 billion.
• Third-quarter results exceeded expectations, with organic revenue up 6.2%, adjusted EBIT margin expanding 180 basis points to 16.6%, adjusted EPS rising 25.1% to $1.34, and free cash flow increasing to $793 million.
• Pharmaceutical Diagnostics delivered 13.8% organic growth, while Flyrcado adoption continued to build; management remains confident in its goal of reaching a $500 million annualized Flyrcado revenue run rate exiting 2028. The planned SOFIE Biosciences acquisition is intended to strengthen U.S. radiopharmaceutical distribution, manufacturing control, and the precision-medicine pipeline.
• Patient Care Solutions improved sharply, with organic revenue up 8.8% and margin expanding 480 basis points, but fourth-quarter growth will be muted by a difficult comparison related to a prior-year product-hold release. PCS leadership is changing, and GE HealthCare is still evaluating strategic options for the business, although management said the review timeline is unaffected.
• Management characterized capital-equipment demand and the imaging pipeline as resilient, with backlog up 12% year over year to $23.7 billion, but acknowledged ongoing risks from tariffs, inflation, oil prices, and elevated memory-chip costs. Multi-year supplier agreements are expected to improve component availability and reduce supply-chain volatility into 2027.

GE HealthCare Technologies Stock Down 0.2%

GEHC stock traded down $0.13 during trading on Friday, reaching $76.29. The stock had a trading volume of 1,904,207 shares, compared to its average volume of 4,230,839. The company has a current ratio of 1.30, a quick ratio of 0.97 and a debt-to-equity ratio of 0.86. GE HealthCare Technologies has a 1-year low of $58.75 and a 1-year high of $89.77. The firm has a fifty day moving average price of $68.40 and a 200 day moving average price of $70.11. The company has a market capitalization of $34.46 billion, a P/E ratio of 16.12, a PEG ratio of 1.97 and a beta of 0.73.

GE HealthCare Technologies Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be given a dividend of $0.04 per share. This is a positive change from GE HealthCare Technologies’s previous quarterly dividend of $0.0350. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.16 dividend on an annualized basis and a yield of 0.2%. GE HealthCare Technologies’s dividend payout ratio is currently 3.67%.

GE HealthCare Technologies News Summary

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Strong Q3 performance: GE HealthCare reported adjusted earnings of $1.34 per share, exceeding the $1.20 consensus estimate, while revenue of $5.51 billion surpassed expectations of $5.35 billion and increased 7.2% year over year. GE HealthCare Technologies Shares Gap Up After Strong Earnings
• Positive Sentiment: Improved outlook and broad-based demand: Management raised its 2026 outlook, including approximately 4% organic revenue growth, adjusted EPS of $4.95–$5.05, and at least $1.6 billion in free cash flow. Analysts also highlighted 6.2% organic growth, margin expansion, Pharmaceutical Diagnostics momentum, and potential growth from Flyrcado and the SOFIE acquisition. GE HealthCare: Broad-Based Growth Makes The Bull Case More Compelling
• Positive Sentiment: Higher analyst targets: RBC raised its target from $80 to $90 and maintained an “outperform” rating. Mizuho increased its target to $90 from $85, while BNP Paribas lifted its target to $100 from $96. BTIG Research also forecast strong potential appreciation. BNP Paribas Adjusts Price Target on GE HealthCare Technologies
• Neutral Sentiment: Mixed analyst stance: JPMorgan raised its target from $70 to $80 but retained a “neutral” rating, suggesting that some analysts see less near-term upside after the post-earnings move. JPMorgan GE HealthCare analyst recommendation
• Neutral Sentiment: Valuation comparison: A Zacks analysis compares GEHC with Haemonetics as a potential value investment, but does not introduce a material new company-specific catalyst. GEHC versus HAE value comparison

Wall Street Analyst Weigh In

A number of research firms have issued reports on GEHC. Piper Sandler reiterated a “buy” rating on shares of GE HealthCare Technologies in a report on Wednesday, July 29th. Evercore reiterated an “outperform” rating and issued a $84.00 price objective on shares of GE HealthCare Technologies in a research note on Thursday, July 30th. Barclays boosted their price target on shares of GE HealthCare Technologies from $85.00 to $95.00 and gave the stock an “overweight” rating in a report on Thursday. Needham & Company LLC restated a “buy” rating and issued a $93.00 price objective on shares of GE HealthCare Technologies in a report on Monday, October 5th. Finally, BTIG Research lifted their price objective on shares of GE HealthCare Technologies from $75.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday. Twelve equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat.com, GE HealthCare Technologies currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.57.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc is a global medical technology company that develops and provides products, services and digital solutions for healthcare providers. Its offerings are designed to support the diagnosis, treatment and monitoring of patients across hospitals, outpatient facilities, imaging centers and other care settings.

The company’s portfolio includes medical imaging systems such as computed tomography, magnetic resonance imaging, molecular imaging, surgical imaging and X-ray equipment.